EP
Equine Performance Labs produces equicenta™ CTM, a cryopreserved allograft derived from fetal equine umbilical cord tissue. The injectable product delivers a protein‑rich extracellular matrix scaffold to support repair of joints, tendons, and ligaments in horses, and is administered by licensed veterinarians for lameness treatment and performance enhancement. The company monetizes the therapy through direct sales of single‑dose vials to veterinary practices and equine health facilities.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Equine Performance Labs produces equicenta™ CTM, a cryopreserved allograft derived from fetal equine umbilical cord tissue for targeted repair of joints, tendons, and ligaments. The product delivers a protein‑rich extracellular matrix scaffold that supports natural tissue regeneration and improves mobility while minimizing adverse reactions. It is processed in‑house under human‑tissue standards, ensuring consistent quality, sterility, and immediate availability for veterinary use.